LOS ANGELES–(BUSINESS WIRE)–MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF) today released its consolidated financial results third quarter 2020 ended March 28, 2020. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Management Commentary

“We continued to make significant progress during the third quarter by delivering top-line growth, reducing our corporate overhead and attracting capital to support our strategic plan,” said MedMen Interim Chief Executive Officer Tom Lynch. “We are encouraged by the steps the business has taken to focus on disciplined growth and profitability amidst a challenging and unprecedented global environment. Through the strength of the MedMen brand and the capital partners that continue to support the Company, we are well-positioned to execute on our goal of being the leading cannabis retailer.”

Third Quarter Fiscal 2020 Review

Financials:

• Revenue: Systemwide revenue across MedMen’s operations in California, Nevada, New York, Illinois and Florida increased to $45.9 million for the quarter, up 41% year-over-year
• Corporate SG&A: Corporate SG&A totaled $17.3 million, a 35% decrease from previous quarter, and 51% decrease from the prior year period. Subsequent to the quarter end, the Company further reduced corporate SG&A through an additional approximate 25% reduction in corporate headcount. In aggregate, the Company has reduced overall corporate SG&A by over $100 million on an annualized basis since the initial cost cutting efforts began in the fiscal second quarter of 2019.
• Adjusted EBITDA: The Company reported an Adjusted EBITDA loss of $20.7 million for the quarter, an improvement over the Adjusted EBITDA loss of $35.1 million in the previous quarter. The Company’s cultivation and manufacturing facilities contributed to $12.9 million of the total Adjusted EBITDA loss.
• Adjusted Retail EBITDA: Across its national retail footprint, the Company recorded a four-wall Adjusted EBITDA margin after local taxes and distribution expenses of 5%, compared to an 8% loss in the previous quarter, primarily driven by reduced payroll costs and local taxes.
• Retail Cash Flow: For the month of March, the Company recorded positive after-tax cash flow (including estimated state, local and federal taxes) across its national retail footprint due to gross margin improvements, cost optimization initiatives and reduction in local taxes. The Company’s two highest-performing stores, Evanston, IL and West Hollywood, CA, combined for an after-tax cash flow margin of 17% during the month of March.
• Balance Sheet: As of March 28, 2020, current assets totaled $123.9 million and included cash and cash equivalents of $31.8 million
• Capital Markets: During the quarter, the Company raised $7.8 million in gross proceeds under the equity offering announced in December 2019, received $12.5 million in additional gross proceeds under its GGP senior secured convertible note facility and generated gross proceeds of $17.0 million through the sale of non-core assets

Retail Highlights:

• California: California retail revenue totaled $29.6 million for the third quarter, representing a 19% increase from the same period last year. On a same-store basis, California retail stores are up 5% from the same period last year. The Beverly Hills, Santa Ana, LAX, Abbot Kinney and Downtown Los Angeles locations were up 13%, 28%, 27%, 13% and 14%, respectively, compared to the same period last year.
• Illinois: The Company currently operates two stores in Illinois with locations in Oak Park and Evanston. Illinois became the Company’s second highest-grossing market during the quarter, with retail revenue totaling $6.7 million for the quarter, representing a 282% sequential increase over the second quarter, despite limited store hours due to product shortages across the state. Subsequent to the quarter end, the Company secured additional vendor support for increased product in anticipation of expanded store hours.
• Nevada: Nevada retail revenue totaled $4.7 million for the third quarter, representing a 5% increase from same period last year. During the quarter, the Company temporarily shut down retail operations in its Downtown Las Vegas and Paradise locations due to COVID-19.
• Florida: The Company operated eight retail locations in Florida during the third quarter. Due to improvements at its Eustis facility, the Company was able to enhance its inventory levels, leading to a 33% sequential revenue increase over the second quarter. Subsequent to the quarter end, the Company temporarily closed five of the eight locations to redirect limited product to higher traffic locations.
• Massachusetts: The Company’s Fenway location is pending final regulatory approval and construction is anticipated to begin in calendar year 2020. In Newton, Massachusetts MedMen has signed a lease on a retail location and now is awaiting regulatory approvals.
• New York: The Company operates four medical dispensaries in the state, with a flagship location on Fifth Avenue near Bryant Park.
• Arizona: The Company is currently in the process of divesting its Arizona footprint, which includes three retail locations and various cultivation and manufacturing operations.
• COVID-19: On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. While the ultimate severity of the outbreak and its impact on the economic environment is uncertain, the Company is monitoring the situation closely and is taking necessary steps to ensure the safety of its employees and customers. Despite being deemed as an essential retailer in its core markets, the Company has experienced a negative impact on sales in certain markets as a result of shelter-at-home orders, social distancing efforts, caps on maximum allowable people within a retail establishment, declining tourism and required modifications to store operations. Certain markets, such as California and Nevada, experienced a greater impact on sales due to reduced foot traffic in certain locations. Other markets, such as Illinois, Florida and New York have not been significantly impacted by COVID-19 and in some cases, stores in those markets have generated increased sales subsequent to the quarter end.

Capital Markets and Financing Activities:

• Credit Facility: On March 30, 2020, the Company announced it closed on $12.5 million in additional gross proceeds under its $250.0 million senior secured convertible debt facility (the “Facility”) led by funds affiliated with Gotham Green Partners (collectively, “GGP”). Subsequent to the quarter end, GGP funded an additional $2.5 million under the Facility. In aggregate, GGP and co-investors have invested $150.0 million into the Company under the Facility to date.
• Equity Investment: On January 14, 2020, the Company announced the closing of its $20.0 million offering of Class B Subordinate Voting Shares at a price per share of $0.43. Of the total offering, $7.8 million was received by the Company during the quarter.
• Definitive Agreement on Sale of Non-Core Asset: On February 25, 2020 the Company entered into definitive agreements to assign its rights to acquire a licensed cultivation and manufacturing facility in Hillcrest, Illinois (“Hillcrest Facility”) for total gross proceeds of $17.0 million (“Hillcrest Transaction”). The Company previously received the right to acquire the Hillcrest Facility as part of its merger termination agreement with PharmaCann, LLC (“PharmaCann”).
• Secured Term Loan Amendment: On January 14, 2020, the Company announced the execution and closing of definitive documentation for amendments to the terms and conditions of the $77.8 million senior secured term loan with funds managed by Stable Road and its affiliates.

Corporate Governance:

• MedMen 2020 Annual General Meeting Results: The Annual General Meeting of MedMen shareholders was held on February 21, 2020 in Toronto, Canada under Executive Chairman, Ben Rose. Shareholders adopted all the resolutions submitted for approval. Shareholders re-elected Ben Rose, Adam Bierman and Jay Brown to the Board of Directors and added new members Mel Elias, Cameron Smith, and Chris Ganan. Jay Brown subsequently resigned from the Board of Directors on March 24, 2020. MNP LLP was re-appointed as the auditors of the Company.
• Management Changes: Effective February 1, 2020, Adam Bierman, Co-Founder and Chief Executive Officer stepped down as Chief Executive Officer and the Board of Directors named the Company’s Chief Technology Officer, Ryan Lissack, as Interim Chief Executive Officer. On March 30, 2020, the Company appointed Tom Lynch as Interim Chief Executive Officer and Chief Restructuring Officer, succeeding Ryan Lissack. Tim Bossidy was appointed as Interim Chief Operating Officer.
• Super Voting Shares: As part of his resignation, former Chief Executive Officer, Adam Bierman, agreed to surrender his Class A Super Voting shares. Following expiration of the limited proxy granted by Andrew Modlin to Ben Rose, MedMen will only have one class of outstanding shares, Class B subordinate voting shares, each of which entitle the holder to one vote.
• Board Additions: During the quarter, the Company announced three additions to its Board of Directors
  • Mel Elias, former President and CEO of The Coffee Bean & Tea Leaf
  • Cameron Smith, a private angel investor and advisor focused on health food
  • Errol Schweizer, former Vice President of Grocery at Whole Foods Market

Subsequent Events:

• Board of Directors: Effective May 26, 2020, the Company appointed Niki Christoff to its Board of Directors. Ms. Christoff currently serves as a Senior Vice President of Strategy and Government Relations at Salesforce, where she has held the role since 2017. Prior to joining Salesforce, Ms. Christoff served as Senior Director of Public Policy at Uber. Ms. Christoff also held a number of positions at Google over a span of eight years, including most recently, serving as Director of Global Communications and Public Affairs. In 2019, Ms. Christoff was named one of Fortune’s “25 Most Powerful Women in Politics.”

Transition to United States Generally Accepted Accounting Principles (“U.S. GAAP”):

The Company is required by the U.S. Securities and Exchange Commission (“SEC”) to test whether it continues to qualify as a foreign private issuer as of the last business day of every fiscal second quarter. As of December 28, 2019, the Company no longer met the qualification as a foreign private issuer as a result of more than 50% of the Company’s outstanding voting securities being held by residents of the United States. Effective June 27, 2020, MedMen will be considered a United States domestic issuer and non-accelerated filer under the rules of the SEC. Accordingly, the Company will prepare its audited consolidated financial statements for the 52 weeks ended June 27, 2020 in accordance with U.S. GAAP, with such change being applied retrospectively. The extent of the impact of this change in accounting framework has not yet been quantified by the Company.

ADDITIONAL INFORMATION

Additional information relating to the Company’s fiscal third quarter 2020 results is available on SEDAR at www.sedar.com in the Company’s Interim Financial Statements and Management Discussion & Analysis (“MD&A”) for the quarter.

MedMen refers to certain non-IFRS financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), adjusted EBITDA (defined as earnings before interest, taxes, depreciation, amortization, less certain non-cash equity compensation expense, including one-time transaction fees and all other non-cash items), four-wall retail gross margins, Retail Cash Flow and Corporate SG&A. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers.

Please see the “Supplemental Information (Unaudited) Regarding Non-IFRS Financial Measures” at the end of this press release and the MD&A for more detailed information regarding non-IFRS financial measures.

CONFERENCE CALL AND WEBCAST:

MedMen Enterprises will host a conference call and audio webcast with Interim Chief Executive Officer Tom Lynch and Chief Financial Officer Zeeshan Hyder today at 5:00 pm Eastern to discuss the financial results in further detail.

Webcast Information:

A live audio webcast of the call will be available on the Events and Presentations section of MedMen’s website at: https://investors.medmen.com/events-and-presentations/default.aspx and will be archived for replay.

Calling Information:

Toll Free Dial-In Number: (844) 559-7829

International Dial-In Number: (647) 689-5387

Conference ID: 7361758

ABOUT MEDMEN:

MedMen is North America’s premium cannabis retailer with flagship locations in Los Angeles, Las Vegas, Chicago and New York. Through a robust selection of high-quality products, including MedMen-owned brands [statemade], LuxLyte and MedMen Red, and a team of cannabis-educated associates, MedMen has defined the next generation discovery platform for cannabis and all its benefits. MedMen’s industry-leading technology enables a fully compliant, owned-and-operated delivery service and MedMen Buds, a loyalty program. MedMen believes that a world where cannabis is legal and regulated is safer, healthier and happier. Learn more at www.medmen.com.

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs and assumptions regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “target of”, “objectives”, “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, expectations regarding the timing and results of the Company’s focus on retail operations, divestiture of its Arizona footprint, continued cost cutting efforts, emphasis on four-wall economics, and other considerations that could impact achieving positive EBITDA.

This forward-looking information is based on certain assumptions made by management and other factors used by management in developing such information.

Although MedMen believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf are expressly qualified in its entirety by this notice.

Non-IFRS Measures

This press release uses certain non-IFRS measures. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision-making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These measures include EBITDA, which is defined as net income or loss adjusted for net interest and other financing costs, provision for income taxes, and amortization and depreciation, and Retail Cash Flow which is defined as net income adjusted for amortization and depreciation.

Management believes that these non-IFRS financial measures assess the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results.

As there are no standardized methods of calculating these non-IFRS financial measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, these non-IFRS financial measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

MEDMEN ENTERPRISES INC.
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
MARCH 28, 2020 AND JUNE 29, 2019
(Amounts Expressed in United States Dollars Unless Otherwise Stated)
		March 28, 2020				June 29, 2019
ASSETS
Current Assets:
Cash and Cash Equivalents		$	31,802,450			$	33,753,751
Restricted Cash			9,873				55,618
Accounts Receivable			1,032,639				1,487,430
Current Portion of Prepaid Rent – Related Party			–				1,580,205
Prepaid Expenses			5,358,968				14,147,213
Derivative Assets			–				5,213,126
Income Taxes Receivable			3,165,363				3,459,019
Biological Assets			1,901,221				3,076,158
Inventory			19,396,885				29,176,192
Assets Held for Sale			46,807,244				–
Other Current Assets			10,590,123				18,913,039
Due from Related Party			3,851,589				4,921,455
Total Current Assets			123,916,355				115,783,206
Non-Current Assets:
Prepaid Rent – Related Party, Net of Current Portion			–				4,327,077
Property and Equipment, Net			437,912,875				220,989,461
Intangible Assets, Net			162,456,527				175,552,837
Goodwill			61,322,038				85,560,531
Other Assets			25,792,912				32,417,123
Total Non-Current Assets			687,484,352				518,847,029
TOTAL ASSETS		$	811,400,707			$	634,630,235
LIABILITIES AND SHAREHOLDERS’ EQUITY
LIABILITIES:
Current Liabilities:
Accounts Payable and Accrued Liabilities		$	66,559,579			$	49,794,041
Income Taxes Payable			37,777,329				16,873,177
Other Current Liabilities			12,893,303				10,550,240
Derivative Liabilities			15,621,552				9,343,485
Current Portion of Lease Liabilities			13,453,542				2,502,813
Current Portion of Notes Payable			16,942,303				20,229,641
Liabilities Held for Sale			16,335,846				–
Due to Related Party			4,922,970				5,640,817
Total Current Liabilities			184,506,424				114,934,214
Non-Current Liabilities:
Lease Liabilities, Net of Current Portion			305,939,495				95,726,766
Other Non-Current Liabilities			9,974,671				30,877,794
Deferred Tax Liabilities			26,407,392				24,578,609
Senior Secured Convertible Credit Facility			136,785,688				90,270,837
Notes Payable, Net of Current Portion			75,126,109				77,392,749
Total Non-Current Liabilities			554,233,355				318,846,755
TOTAL LIABILITIES			738,739,779				433,780,969
SHAREHOLDERS’ EQUITY:
Share Capital			700,322,430				556,651,469
Contributed Surplus			78,209,834				63,026,656
Accumulated Deficit			(523,157,889	)			(383,622,726	)
Total Equity Attributable to Shareholders of MedMen Enterprises Inc.			255,374,375				236,055,399
Non-Controlling Interest			(182,713,447	)			(35,206,133	)
TOTAL SHAREHOLDERS’ EQUITY			72,660,928				200,849,266
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	811,400,707			$	634,630,235

	MEDMEN ENTERPRISES INC.
	UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
	13 AND 39 WEEKS ENDED MARCH 28, 2020 AND MARCH 30, 2019
	(Amounts Expressed in United States Dollars Unless Otherwise Stated)
			13 Weeks Ended									39 Weeks Ended
			March 28, 2020				March 30, 2019					March 28, 2020				March 30, 2019
	Revenue		$	45,941,160			$	32,548,880				$	129,677,038			$	83,426,370
	Cost of Goods Sold			32,851,115				18,683,661					89,755,783				44,872,729
	Gross Profit Before Fair Value Adjustments			13,090,045				13,865,219					39,921,255				38,553,641
	Realized Fair Value of Inventory Sold			(1,948,273	)			(5,655,150	)				(7,425,278	)			(7,852,073	)
	Unrealized Gain on Changes in Fair Value of Biological Assets			4,330,067				9,793,860					12,788,755				12,676,775
	Gross Profit			15,471,839				18,003,929					45,284,732				43,378,343
	Expenses:
	General and Administrative			38,075,000				59,960,174					137,905,424				189,847,849
	Sales and Marketing			1,047,996				6,718,248					10,441,725				20,120,773
	Depreciation and Amortization			14,653,049				4,512,196					38,539,113				10,342,319
	Total Expenses			53,776,045				71,190,618					186,886,262				220,310,942
	Loss from Operations			(38,304,206	)			(53,186,689	)				(141,601,530	)			(176,932,599	)
	Other Expense (Income):
	Interest Expense			13,286,915				2,645,309					37,152,380				7,034,634
	Interest Income			(126,089	)			(123,068	)				(760,810	)			(407,957	)
	Amortization of Debt Discount and Loan Origination Fees			1,908,452				2,328,353					9,123,700				4,678,679
	Change in Fair Value of Derivatives			(3,171,622	)			3,861,290					(3,693,214	)			(2,301,817	)
	Unrealized Gain on Changes in Fair Value of Investments and Assets Held for Sale			(86,124	)			(1,100,000	)				(16,600,605	)			(2,294,000	)
	Unrealized Gain on Changes in Fair Value of Contingent Consideration			962,791				–					(924,355	)			–
	Other Expense			2,199,360				(767,815	)				28,667,395				2,490,234
	Total Other Expense			14,973,683				6,844,069					52,964,491				9,199,773
	Loss from Continuing Operations Before Provision for Income Taxes			(53,277,889	)			(60,030,758	)				(194,566,021	)			(186,132,372	)
	Provision for Income Taxes			15,501,118				2,481,831					27,582,121				6,077,056
	Net Loss and Comprehensive Loss from Continuing Operations			(68,779,007	)			(62,512,589	)				(222,148,142	)			(192,209,428	)
	Net Loss from Discontinued Operations, Net of Taxes			(8,164,163	)			(560,109	)				(33,863,639	)			(1,929,714	)
	Net Loss and Comprehensive Loss			(76,943,170	)			(63,072,698	)				(256,011,781	)			(194,139,142	)
	Net Loss and Comprehensive Loss Attributable to Non-Controlling Interest			(37,009,149	)			(39,336,053	)				(143,992,540	)			(139,239,701	)
	Net Loss and Comprehensive Loss Attributable to Shareholders of MedMen Enterprises Inc.		$	(39,934,021	)		$	(23,736,645	)			$	(112,019,241	)		$	(54,899,441	)
	Loss Per Share – Basic and Diluted:
	From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.		$	(0.10	)		$	(0.20	)			$	(0.32	)		$	(0.80	)
	From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.		$	(0.03	)		$	(0.00	)			$	(0.14	)		$	(0.03	)
	Weighted-Average Shares Outstanding – Basic and Diluted			315,384,911				118,853,840					242,979,371				65,930,969

	MEDMEN ENTERPRISES INC.
	UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
	39 WEEKS ENDED MARCH 28, 2020 AND MARCH 30, 2019
	(Amounts Expressed in United States Dollars Unless Otherwise Stated)
			39 Weeks Ended
			March 28,				March 30,
			2020				2019
	CASH FLOW FROM OPERATING ACTIVITIES:
	Net Loss and Comprehensive Loss from Continuing Operations		$	(222,148,142	)		$	(192,209,428	)
	Adjustments to Reconcile Net Loss and Comprehensive Loss to Net Cash Used in Continued Operating Activities:
	Unrealized Gain on Changes in Fair Value of Biological Assets			(12,788,755	)			(12,676,775	)
	Deferred Tax Expense			428,458				–
	Interest Expense			37,152,380				–
	Realized Fair Value of Inventory Sold			(7,425,278	)			7,852,073
	Depreciation and Amortization			43,050,999				11,277,031
	Loss on Disposals of Non-Current Assets			1,475,381				1,635,598
	Amortization of Debt Discount and Loan Origination Fees			9,123,700				4,562,915
	Change in Fair Value of Contingent Consideration			(924,355	)			–
	Accretion of Deferred Gain on Sale of Property			(756,253	)			(246,133	)
	Unrealized Gain on Changes in Fair Value of Investments and Assets Held for Sale			(16,600,605	)			(2,294,000	)
	Loss on Extinguishment of Debt, Debt Modification and Liabilities			20,814,006				1,174,922
	Share-Based Compensation			10,845,454				28,702,327
	Shares Issued for Acquisition Costs			429,314				1,112,820
	Change in Fair Value of Derivatives			(3,693,214	)			(2,301,817	)
	Changes in Operating Assets and Liabilities:
	Accounts Receivable			159,139				(225,004	)
	Prepaid Rent – Related Party			–				1,263,333
	Prepaid Expenses			8,452,369				(9,294,732	)
	Income Taxes Receivable			293,206				–
	Biological Assets			20,636,748				733,280
	Inventory			5,655,527				(11,734,517	)
	Other Current Assets			6,035,072				(7,051,088	)
	Due from Related Party			(151,788	)			(6,620,425	)
	Other Assets			(13,346,268	)			873,910
	Accounts Payable and Accrued Liabilities			33,364,240				15,442,047
	Income Taxes Payable			29,108,740				–
	Other Current Liabilities			(722,678	)			(12,611,720	)
	Due to Related Party			(5,607,959	)			(4,217,624	)
	Other Non-Current Liabilities			–				1,705
	NET CASH USED IN CONTINUED OPERATING ACTIVITIES			(57,140,562	)			(186,851,302	)
								–
	Net Cash Provided by Discontinued Operating Activities			2,896,876				2,635,686
	NET CASH USED IN OPERATING ACTIVITIES			(54,243,686	)			(184,215,616	)
	CASH FLOWS FROM INVESTING ACTIVITIES:
	Purchases of Property and Equipment			(50,795,688	)			(81,474,412	)
	Internally-Developed Software Costs Capitalized			(3,701,764	)			–
	Proceeds from Sale of Assets Held for Sale			21,947,796				–
	Purchase of Investments			–				(8,919,791	)
	Proceeds from Sale of Property			21,875,000				96,373,319
	Proceeds from Sale of Investments			12,500,000				–
	Acquisition of Businesses, Net of Cash Acquired			(1,000,000	)			(49,224,060	)
	Additions to Restricted Cash			45,745				4,319,347
								–
	NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES			871,089				(38,925,597	)
								–
	Net Cash Used in Discontinued Investing Activities			(1,827,239	)			(723,611	)
	NET CASH USED IN INVESTING ACTIVITIES			(956,150	)			(39,649,208	)
	CASH FLOWS FROM FINANCING ACTIVITIES:
	Exercise of Warrants for MedMen Corp Redeemable Shares			–				8,521,268
	Issuance of Subordinate Voting Shares for Cash			62,593,190				115,289,679
	Payment of Loan Amendment Fee			(500,000	)			–
	Proceeds from Issuance of Senior Secured Convertible Credit Facility			47,500,000				–
	Proceeds from Issuance of Notes Payable			2,750,000				93,943,539
	Principal Repayments of Notes Payable			(15,598,610	)			(48,863,155	)
	Lease Liability Payments			(32,351,797	)			(560,242	)
	Interest Paid on Notes Payable and Senior Secured Convertible Credit Facility			(7,631,128	)			–
	Debt Issuance Costs			(1,584,913	)			(2,019,472	)
	(Distributions to) Contributions from Non-Controlling Interest			(310,633	)			290,000
								–
	NET CASH PROVIDED BY FINANCING ACTIVITIES			54,866,109				166,601,617
								–
	NET DECREASE IN CASH AND CASH EQUIVALENTS			(333,727	)			(57,263,207	)
	Cash Included in Assets Held for Sale			(1,617,574	)			–
	Cash and Cash Equivalents, Beginning of Period			33,753,751				79,159,970
								–
	CASH AND CASH EQUIVALENTS, END OF PERIOD		$	31,802,450			$	21,896,763

	MEDMEN ENTERPRISES INC.
	NON-IFRS RECONCILIATION
	13 AND 39 WEEKS ENDED MARCH 28, 2020 AND MARCH 30, 2019
	(Amounts Expressed in United States Dollars Unless Otherwise Stated)
			13 Weeks Ended								39 Weeks Ended
			March 28, 2020				March 30, 2019				March 28, 2020				March 30, 2019
	Net Loss from Continuing Operations (IFRS)		$	(68,779,007	)		$	(62,512,589	)		$	(222,148,142	)		$	(192,209,428	)
	Add (Deduct) Impact of:
	Transaction Costs and Other One-Time Costs			3,171,545				3,360,657				21,986,665				9,018,336
	Share-Based Compensation			1,784,043				6,048,427				10,747,093				28,702,328
	Other Non-Cash Operating Costs			(2,711,570	)			(2,145,235	)			(2,500,657	)			(6,930,285	)
	Total Adjustments			2,244,018				7,263,849				30,233,101				30,790,379
	Adjusted Net Loss from Continuing Operations (Non-IFRS)		$	(66,534,989	)		$	(55,248,740	)		$	(191,915,041	)		$	(161,419,049	)
	Net Loss from Continuing Operations (IFRS)		$	(68,779,007	)		$	(62,512,589	)		$	(222,148,142	)		$	(192,209,428	)
	Add (Deduct) Impact of:
	Net Interest and Other Financing Costs			13,160,827				2,289,496				36,219,847				6,393,932
	Provision for Income Taxes			15,501,118				2,481,832				28,053,159				6,077,057
	Amortization and Depreciation			17,151,193				7,557,280				51,852,527				16,188,394
	Total Adjustments			45,813,138				12,328,608				116,125,533				28,659,383
	EBITDA from Continuing Operations (Non-IFRS)		$	(22,965,869	)		$	(50,183,981	)		$	(106,022,609	)		$	(163,550,045	)
	EBITDA from Continuing Operations (Non-IFRS)		$	(22,965,869	)		$	(50,183,981	)		$	(106,022,609	)		$	(163,550,045	)
	Add (Deduct) Impact of:
	Transaction Costs and Other One-Time Costs			3,171,545				3,360,657				21,986,665				9,018,336
	Share-Based Compensation			1,784,043				6,048,427				10,747,093				28,702,328
	Other Non-Cash Operating Costs			(2,711,570	)			(2,145,235	)			(2,500,657	)			(6,930,285	)
	Total Adjustments			2,244,018				7,263,849				30,233,101				30,790,379
	Adjusted EBITDA from Continuing Operations (Non-IFRS)		$	(20,721,851	)		$	(42,920,132	)		$	(75,789,508	)		$	(132,759,666	)

SOURCE: MedMen Enterprises